InventionMed Statistics
Total Valuation
InventionMed has a market cap or net worth of PLN 32.65 million. The enterprise value is 35.32 million.
Market Cap | 32.65M |
Enterprise Value | 35.32M |
Important Dates
The next estimated earnings date is Friday, November 14, 2025.
Earnings Date | Nov 14, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
InventionMed has 202.79 million shares outstanding.
Current Share Class | 201.79M |
Shares Outstanding | 202.79M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 5.61% |
Owned by Institutions (%) | n/a |
Float | 113.77M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 16.27 |
PB Ratio | 159.43 |
P/TBV Ratio | 282.03 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -9.46 |
EV / Sales | 17.60 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -13.20 |
Financial Position
The company has a current ratio of 0.08, with a Debt / Equity ratio of 13.07.
Current Ratio | 0.08 |
Quick Ratio | 0.08 |
Debt / Equity | 13.07 |
Debt / EBITDA | n/a |
Debt / FCF | -1.00 |
Interest Coverage | -1.02 |
Financial Efficiency
Return on equity (ROE) is -180.23% and return on invested capital (ROIC) is -31.23%.
Return on Equity (ROE) | -180.23% |
Return on Assets (ROA) | -2.76% |
Return on Invested Capital (ROIC) | -31.23% |
Return on Capital Employed (ROCE) | -7.18% |
Revenue Per Employee | 401,392 |
Profits Per Employee | -746,717 |
Employee Count | 5 |
Asset Turnover | 0.05 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -18.93% in the last 52 weeks. The beta is 0.20, so InventionMed's price volatility has been lower than the market average.
Beta (5Y) | 0.20 |
52-Week Price Change | -18.93% |
50-Day Moving Average | 0.17 |
200-Day Moving Average | 0.18 |
Relative Strength Index (RSI) | 47.32 |
Average Volume (20 Days) | 273,343 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, InventionMed had revenue of PLN 2.01 million and -3.73 million in losses. Loss per share was -0.02.
Revenue | 2.01M |
Gross Profit | 1.75M |
Operating Income | -1.70M |
Pretax Income | -3.73M |
Net Income | -3.73M |
EBITDA | -841,474 |
EBIT | -1.70M |
Loss Per Share | -0.02 |
Balance Sheet
The company has 6,230 in cash and 2.68 million in debt, giving a net cash position of -2.67 million or -0.01 per share.
Cash & Cash Equivalents | 6,230 |
Total Debt | 2.68M |
Net Cash | -2.67M |
Net Cash Per Share | -0.01 |
Equity (Book Value) | 204,788 |
Book Value Per Share | 0.00 |
Working Capital | -13.46M |
Cash Flow
In the last 12 months, operating cash flow was -1.96 million and capital expenditures -716,805, giving a free cash flow of -2.67 million.
Operating Cash Flow | -1.96M |
Capital Expenditures | -716,805 |
Free Cash Flow | -2.67M |
FCF Per Share | -0.01 |
Margins
Gross margin is 86.99%, with operating and profit margins of -84.89% and -186.03%.
Gross Margin | 86.99% |
Operating Margin | -84.89% |
Pretax Margin | -186.03% |
Profit Margin | -186.03% |
EBITDA Margin | -41.93% |
EBIT Margin | -84.89% |
FCF Margin | n/a |
Dividends & Yields
InventionMed does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | n/a |
Shareholder Yield | n/a |
Earnings Yield | -11.44% |
FCF Yield | -8.19% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
The last stock split was on September 6, 2022. It was a forward split with a ratio of 4.
Last Split Date | Sep 6, 2022 |
Split Type | Forward |
Split Ratio | 4 |
Scores
InventionMed has an Altman Z-Score of -1.13 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -1.13 |
Piotroski F-Score | 4 |